{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T01:22:47Z","timestamp":1790126567035,"version":"4.0.1"},"reference-count":50,"publisher":"American Diabetes Association","issue":"10","license":[{"start":{"date-parts":[[2024,7,8]],"date-time":"2024-07-08T00:00:00Z","timestamp":1720396800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.diabetesjournals.org\/journals\/pages\/license"}],"content-domain":{"domain":["diabetesjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,10,1]]},"abstract":"<jats:sec>\n                  <jats:title\/>\n                  <jats:p>Treatment with glucagon-like peptide 1 receptor agonists reduces liver steatosis and cardiometabolic risk (CMR). Few data are available on lipid metabolism, and no information is available on the postprandial lipidomic profile. Thus, we investigated how exenatide treatment changes lipid metabolism and composition during fasting and after a mixed-meal tolerance test (MMTT) in adults with severe obesity without diabetes. Thirty individuals (26 females and 4 males, 30\u201360 years old, BMI &amp;gt;40 kg\/m2, HbA1c 5.76%) were assigned (1:1) to diet with exenatide 10 \u03bcg twice daily treatment (n = 15) or without treatment as control (n = 15) for 3 months. Fasting and postprandial lipidomic profile (by liquid chromatography quadrupole time-of-flight mass spectrometry) and fatty acid metabolism (following a 6-h MMTT\/tracer study) and composition (by gas chromatography-mass spectrometry) were evaluated before and after treatment. Both groups had slight weight loss (\u22125.5% vs. \u22121.9%, exenatide vs. control; P = 0.052). During fasting, exenatide, compared with control, reduced some ceramides (CERs) and lysophosphatidylcholines (LPCs) previously associated with CMR, while relatively increasing unsaturated phospholipid species (phosphatidylcholine [PC], LPC) with protective effects on CMR, although concentrations of total lipid species were unchanged. During MMTT, both groups showed suppressed lipolysis equal to baseline, but exenatide significantly lowered free fatty acid clearance and postprandial triacyclglycerol (TAG) concentrations, particularly saturated TAGs with 44\u201354 carbons. Exenatide also reduced some postprandial CERs, PCs, and LPCs previously linked to CMR. These changes in lipidomic profile remained statistically significant after adjusting for weight loss. Exenatide improved fasting and postprandial lipidomic profiles associated with CMR mainly by reducing saturated postprandial TAGs and CERs independently of weight loss and diabetes.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Article Highlights<\/jats:title>\n               <\/jats:sec>","DOI":"10.2337\/db23-0972","type":"journal-article","created":{"date-parts":[[2024,7,8]],"date-time":"2024-07-08T16:38:51Z","timestamp":1720456731000},"page":"1605-1614","update-policy":"https:\/\/doi.org\/10.2337\/ada-journal-policies","source":"Crossref","is-referenced-by-count":14,"title":["GLP-1 Receptor Agonist Treatment Improves Fasting and Postprandial Lipidomic Profiles Independently of Diabetes and Weight Loss"],"prefix":"10.2337","volume":"73","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5862-3794","authenticated-orcid":false,"given":"Giuseppe","family":"Della Pepa","sequence":"first","affiliation":[{"name":"1National Research Council, Institute of Clinical Physiology, Pisa, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B\u00e1rbara G.","family":"Patr\u00edcio","sequence":"additional","affiliation":[{"name":"1National Research Council, Institute of Clinical Physiology, Pisa, Italy"},{"name":"2Sant\u2019Anna School of Advanced Studies, Pisa, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabrizia","family":"Carli","sequence":"additional","affiliation":[{"name":"1National Research Council, Institute of Clinical Physiology, Pisa, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Sabatini","sequence":"additional","affiliation":[{"name":"1National Research Council, Institute of Clinical Physiology, Pisa, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brenno","family":"Astiarraga","sequence":"additional","affiliation":[{"name":"3Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy"},{"name":"4Pere Virgili Institute for Health Research, Terragona, Spain"},{"name":"5CIBER de Diabetes y Enfermedades Metab\u00f3licas Asociadas, Instituto de Salud Carlos III, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1384-1584","authenticated-orcid":false,"given":"Ele","family":"Ferrannini","sequence":"additional","affiliation":[{"name":"1National Research Council, Institute of Clinical Physiology, Pisa, Italy"},{"name":"3Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefania","family":"Camastra","sequence":"additional","affiliation":[{"name":"3Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2594-1651","authenticated-orcid":false,"given":"Amalia","family":"Gastaldelli","sequence":"additional","affiliation":[{"name":"1National Research Council, Institute of Clinical Physiology, Pisa, Italy"},{"name":"2Sant\u2019Anna School of Advanced Studies, Pisa, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1167","published-online":{"date-parts":[[2024,7,8]]},"reference":[{"key":"2024092018510640300_B1","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1161\/CIRCULATIONAHA.117.028136","article-title":"Cardiovascular actions and clinical outcomes with glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors","volume":"136","author":"Nauck","year":"2017","journal-title":"Circulation"},{"key":"2024092018510640300_B2","doi-asserted-by":"crossref","first-page":"5820","DOI":"10.3390\/ijms21165820","article-title":"Gut-pancreas-liver axis as a target for treatment of NAFLD\/NASH","volume":"21","author":"Svegliati-Baroni","year":"2020","journal-title":"Int J Mol Sci"},{"key":"2024092018510640300_B3","doi-asserted-by":"crossref","first-page":"2049","DOI":"10.1007\/s00125-006-0340-2","article-title":"Vildagliptin therapy reduces postprandial intestinal triglyceride-rich lipoprotein particles in patients with type 2 diabetes","volume":"49","author":"Matikainen","year":"2006","journal-title":"Diabetologia"},{"key":"2024092018510640300_B4","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1111\/dom.14328","article-title":"Effects of liraglutide on the metabolism of triglyceride-rich lipoproteins in type 2 diabetes","volume":"23","author":"Taskinen","year":"2021","journal-title":"Diabetes Obes Metab"},{"key":"2024092018510640300_B5","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1111\/dom.13487","article-title":"Liraglutide treatment improves postprandial lipid metabolism and cardiometabolic risk factors in humans with adequately controlled type 2 diabetes: a single-centre randomized controlled study","volume":"21","author":"Matikainen","year":"2019","journal-title":"Diabetes Obes Metab"},{"key":"2024092018510640300_B6","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1210\/jc.2018-01176","article-title":"Lixisenatide reduces chylomicron triacylglycerol by increased clearance","volume":"104","author":"Whyte","year":"2019","journal-title":"J Clin Endocrinol Metab"},{"key":"2024092018510640300_B7","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1111\/dom.13120","article-title":"Semaglutide improves postprandial glucose and lipid metabolism, and delays first-hour gastric emptying in subjects with obesity","volume":"20","author":"Hjerpsted","year":"2018","journal-title":"Diabetes Obes Metab"},{"key":"2024092018510640300_B8","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1172\/JCI23621","article-title":"Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease","volume":"115","author":"Donnelly","year":"2005","journal-title":"J Clin Invest"},{"key":"2024092018510640300_B9","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1016\/S0140-6736(15)00803-X","article-title":"Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study","volume":"387","author":"Armstrong","year":"2016","journal-title":"Lancet"},{"key":"2024092018510640300_B10","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/j.jhep.2015.08.038","article-title":"Glucagon-like peptide 1 decreases lipotoxicity in non-alcoholic steatohepatitis","volume":"64","author":"Armstrong","year":"2016","journal-title":"J Hepatol"},{"key":"2024092018510640300_B11","doi-asserted-by":"crossref","first-page":"2028","DOI":"10.1002\/hep.28827","article-title":"Exenatide improves both hepatic and adipose tissue insulin resistance: a dynamic positron emission tomography study","volume":"64","author":"Gastaldelli","year":"2016","journal-title":"Hepatology"},{"key":"2024092018510640300_B12","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1007\/s00125-012-2738-3","article-title":"Direct effect of GLP-1 infusion on endogenous glucose production in humans","volume":"56","author":"Seghieri","year":"2013","journal-title":"Diabetologia"},{"key":"2024092018510640300_B13","doi-asserted-by":"crossref","first-page":"e13695","DOI":"10.1111\/eci.13695","article-title":"Adipose tissue insulin resistance and lipidome alterations as the characterizing factors of non-alcoholic steatohepatitis","volume":"52","author":"Guerra","year":"2022","journal-title":"Eur J Clin Invest"},{"key":"2024092018510640300_B14","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1038\/s41575-021-00502-9","article-title":"Metabolomics and lipidomics in NAFLD: biomarkers and non-invasive diagnostic tests","volume":"18","author":"Masoodi","year":"2021","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"2024092018510640300_B15","doi-asserted-by":"crossref","first-page":"2424","DOI":"10.1161\/ATVBAHA.116.307497","article-title":"Circulating ceramides predict cardiovascular outcomes in the population-based FINRISK 2002 cohort","volume":"36","author":"Havulinna","year":"2016","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"2024092018510640300_B16","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.jacl.2020.01.005","article-title":"Ceramides and risk of major adverse cardiovascular events: a meta-analysis of longitudinal studies","volume":"14","author":"Mantovani","year":"2020","journal-title":"J Clin Lipidol"},{"key":"2024092018510640300_B17","doi-asserted-by":"crossref","first-page":"e002395","DOI":"10.1136\/bmjdrc-2021-002395","article-title":"Ceramides and phospholipids are downregulated with liraglutide treatment: results from the LiraFlame randomized controlled trial","volume":"9","author":"Zobel","year":"2021","journal-title":"BMJ Open Diabetes Res Care"},{"key":"2024092018510640300_B18","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1186\/s12933-021-01431-2","article-title":"Pharmacometabolomic profiles in type 2 diabetic subjects treated with liraglutide or glimepiride","volume":"20","author":"Jendle","year":"2021","journal-title":"Cardiovasc Diabetol"},{"key":"2024092018510640300_B19","doi-asserted-by":"crossref","first-page":"677202","DOI":"10.3389\/fendo.2022.677202","article-title":"The changes of lipidomic profiles reveal therapeutic effects of exenatide in patients with type 2 diabetes","volume":"13","author":"Zhang","year":"2022","journal-title":"Front Endocrinol (Lausanne)"},{"key":"2024092018510640300_B20","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1186\/s12933-023-01845-0","article-title":"Liraglutide reduces plasma dihydroceramide levels in patients with type 2 diabetes","volume":"22","author":"Denimal","year":"2023","journal-title":"Cardiovasc Diabetol"},{"key":"2024092018510640300_B21","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1111\/dom.12836","article-title":"Effect of exenatide on postprandial glucose fluxes, lipolysis, and \u03b2-cell function in non-diabetic, morbidly obese patients","volume":"19","author":"Camastra","year":"2017","journal-title":"Diabetes Obes Metab"},{"key":"2024092018510640300_B22","doi-asserted-by":"crossref","first-page":"e3798","DOI":"10.1002\/dmrr.3798","article-title":"Clusters of adipose tissue dysfunction in adults with type 2 diabetes identify those with worse lipidomic profile despite similar glycaemic control","volume":"40","author":"Della Pepa","year":"2024","journal-title":"Diabetes Metab Res Rev"},{"key":"2024092018510640300_B23","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1381\/096089206777346673","article-title":"Estimating blood volume in obese and morbidly obese patients","volume":"16","author":"Lemmens","year":"2006","journal-title":"Obes Surg"},{"key":"2024092018510640300_B24","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1001\/jamacardio.2020.0013","article-title":"A new equation for calculation of low-density lipoprotein cholesterol in patients with normolipidemia and\/or hypertriglyceridemia","volume":"5","author":"Sampson","year":"2020","journal-title":"JAMA Cardiol"},{"key":"2024092018510640300_B25","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.2337\/diabetes.52.7.1641","article-title":"What does the measurement of whole-body fatty acid rate of appearance in plasma by using a fatty acid tracer really mean?","volume":"52","author":"Mittendorfer","year":"2003","journal-title":"Diabetes"},{"key":"2024092018510640300_B26","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1186\/s13059-018-1439-8","article-title":"Hepatic steatosis risk is partly driven by increased de novo lipogenesis following carbohydrate consumption","volume":"19","author":"Sanders","year":"2018","journal-title":"Genome Biol"},{"key":"2024092018510640300_B27","doi-asserted-by":"crossref","first-page":"1796","DOI":"10.1007\/s00125-023-05929-0","article-title":"Gut hormone-based pharmacology: novel formulations and future possibilities for metabolic disease therapy","volume":"66","author":"Tsch\u00f6p","year":"2023","journal-title":"Diabetologia"},{"key":"2024092018510640300_B28","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1177\/0091270009354996","article-title":"Population pharmacokinetics of liraglutide, a once-daily human glucagon-like peptide-1 analog, in healthy volunteers and subjects with type 2 diabetes, and comparison to twice-daily exenatide","volume":"50","author":"Watson","year":"2013","journal-title":"J Clin Pharmacol"},{"key":"2024092018510640300_B29","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1172\/JCI44442","article-title":"Lipid profiling identifies a triacylglycerol signature of insulin resistance and improves diabetes prediction in humans","volume":"121","author":"Rhee","year":"2011","journal-title":"J Clin Invest"},{"key":"2024092018510640300_B30","doi-asserted-by":"crossref","first-page":"4289","DOI":"10.3390\/nu13124289","article-title":"Changes in circulating metabolites during weight loss and weight loss maintenance in relation to cardiometabolic risk","volume":"13","author":"Papandreou","year":"2021","journal-title":"Nutrients"},{"key":"2024092018510640300_B31","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1046\/j.1365-2796.1999.00548.x","article-title":"Postprandial lipoprotein metabolism and atherosclerosis","volume":"246","author":"Karpe","year":"1999","journal-title":"J Intern Med"},{"key":"2024092018510640300_B32","doi-asserted-by":"crossref","first-page":"e121326","DOI":"10.1172\/jci.insight.121326","article-title":"Large-scale plasma lipidomic profiling identifies lipids that predict cardiovascular events in secondary prevention","volume":"3","author":"Mundra","year":"2018","journal-title":"JCI Insight"},{"key":"2024092018510640300_B33","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1172\/JCI131838","article-title":"Machine learning reveals serum sphingolipids as cholesterol-independent biomarkers of coronary artery disease","volume":"130","author":"Poss","year":"2020","journal-title":"J Clin Invest"},{"key":"2024092018510640300_B34","doi-asserted-by":"crossref","first-page":"e85724","DOI":"10.1371\/journal.pone.0085724","article-title":"Glycerophospholipid and sphingolipid species and mortality: the Ludwigshafen Risk and Cardiovascular Health (LURIC) study","volume":"9","author":"Sigruener","year":"2014","journal-title":"PLoS One"},{"key":"2024092018510640300_B35","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1016\/j.jhep.2016.01.002","article-title":"Hepatic ceramides dissociate steatosis and insulin resistance in patients with non-alcoholic fatty liver disease","volume":"64","author":"Luukkonen","year":"2016","journal-title":"J Hepatol"},{"key":"2024092018510640300_B36","doi-asserted-by":"crossref","first-page":"963471","DOI":"10.3389\/fnut.2022.963471","article-title":"Saturated fatty acid biomarkers and risk of cardiometabolic diseases: a meta-analysis of prospective studies","volume":"9","author":"Li","year":"2022","journal-title":"Front Nutr"},{"key":"2024092018510640300_B37","doi-asserted-by":"crossref","first-page":"159125","DOI":"10.1016\/j.bbalip.2022.159125","article-title":"You aren\u2019t IMMUNE to the ceramides that accumulate in cardiometabolic disease","volume":"1867","author":"Varre","year":"2022","journal-title":"Biochim Biophys Acta Mol Cell Biol Lipids"},{"key":"2024092018510640300_B38","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1161\/ATVBAHA.112.246207","article-title":"Exenatide, a glucagon-like peptide-1 receptor agonist, acutely inhibits intestinal lipoprotein production in healthy humans","volume":"32","author":"Xiao","year":"2012","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"2024092018510640300_B39","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.atherosclerosis.2010.05.028","article-title":"Exenatide suppresses postprandial elevations in lipids and lipoproteins in individuals with impaired glucose tolerance and recent onset type 2 diabetes mellitus","volume":"212","author":"Schwartz","year":"2010","journal-title":"Atherosclerosis"},{"key":"2024092018510640300_B40","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.atherosclerosis.2010.04.024","article-title":"One-year treatment with exenatide vs. insulin glargine: effects on postprandial glycemia, lipid profiles, and oxidative stress","volume":"212","author":"Bunck","year":"2010","journal-title":"Atherosclerosis"},{"key":"2024092018510640300_B41","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1111\/dom.14373","article-title":"Oral semaglutide improves postprandial glucose and lipid metabolism, and delays gastric emptying, in subjects with type 2 diabetes","volume":"23","author":"Dahl","year":"2021","journal-title":"Diabetes Obes Metab"},{"key":"2024092018510640300_B42","doi-asserted-by":"crossref","first-page":"1821","DOI":"10.1161\/CIRCULATIONAHA.113.002500","article-title":"Lipidomics profiling and risk of cardiovascular disease in the prospective population-based Bruneck study","volume":"129","author":"Stegemann","year":"2014","journal-title":"Circulation"},{"key":"2024092018510640300_B43","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1016\/j.plipres.2008.03.003","article-title":"Fatty acid composition of adipose tissue and blood in humans and its use as a biomarker of dietary intake","volume":"47","author":"Hodson","year":"2008","journal-title":"Prog Lipid Res"},{"key":"2024092018510640300_B44","doi-asserted-by":"crossref","first-page":"1438","DOI":"10.1210\/jc.2017-01904","article-title":"Postprandial saturated fatty acids increase the risk of type 2 diabetes: a cohort study in a Chinese population","volume":"103","author":"Wang","year":"2018","journal-title":"J Clin Endocrinol Metab"},{"key":"2024092018510640300_B45","doi-asserted-by":"crossref","first-page":"155216","DOI":"10.1016\/j.metabol.2022.155216","article-title":"Increased plasma fatty acid clearance, not fatty acid concentration, is associated with muscle insulin resistance in people with obesity","volume":"132","author":"Cao","year":"2022","journal-title":"Metabolism"},{"key":"2024092018510640300_B46","doi-asserted-by":"crossref","first-page":"bvab118","DOI":"10.1210\/jendso\/bvab118","article-title":"A metabolomic signature of glucagon action in healthy individuals with overweight\/obesity","volume":"5","author":"Vega","year":"2021","journal-title":"J Endocr Soc"},{"key":"2024092018510640300_B47","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1530\/JOE-19-0007","article-title":"Impact of exenatide on mitochondrial lipid metabolism in mice with nonalcoholic steatohepatitis","volume":"241","author":"Kalavalapalli","year":"2019","journal-title":"J Endocrinol"},{"key":"2024092018510640300_B48","doi-asserted-by":"crossref","first-page":"117443","DOI":"10.1016\/j.lfs.2020.117443","article-title":"The mechanisms of lysophosphatidylcholine in the development of diseases","volume":"247","author":"Liu","year":"2020","journal-title":"Life Sci"},{"key":"2024092018510640300_B49","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1016\/j.bbrc.2018.04.106","article-title":"Lipidomic insight into cardiovascular diseases","volume":"504","author":"Kohno","year":"2018","journal-title":"Biochem Biophys Res Commun"},{"key":"2024092018510640300_B50","doi-asserted-by":"crossref","first-page":"1578","DOI":"10.1038\/s42255-023-00880-1","article-title":"Dynamic lipidome alterations associated with human health, disease and ageing","volume":"5","author":"Hornburg","year":"2023","journal-title":"Nat Metab"}],"container-title":["Diabetes"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/diabetesjournals.org\/diabetes\/article-pdf\/73\/10\/1605\/782272\/db230972.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/diabetesjournals.org\/diabetes\/article-pdf\/73\/10\/1605\/782272\/db230972.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,20]],"date-time":"2024-09-20T18:51:34Z","timestamp":1726858294000},"score":1,"resource":{"primary":{"URL":"https:\/\/diabetesjournals.org\/diabetes\/article\/73\/10\/1605\/156952\/GLP-1-Receptor-Agonist-Treatment-Improves-Fasting"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,8]]},"references-count":50,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2024,7,8]]},"published-print":{"date-parts":[[2024,10,1]]}},"URL":"https:\/\/doi.org\/10.2337\/db23-0972","relation":{},"ISSN":["0012-1797","1939-327X"],"issn-type":[{"value":"0012-1797","type":"print"},{"value":"1939-327X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,8]]}}}